Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Focusing on its New Subsidiaries and Intellectual Property
- Lexaria has its patented DehydraTECH drug delivery platform
- The company’s technology is a complementary layer that works with the other research being done on cannabinoids
- Lexaria has a robust IP portfolio and four new subsidiary companies
A drug delivery platform pioneer, Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) has developed and out-licenses its DehydraTECH technology. The company’s technology changes the way in which edible cannabinoids absorb into the body. The DehydraTECH drug delivery platform is patented for cannabidiol and all other non-psychoactive cannabinoids and enables the transportation of bioactive substances via oral ingestion. A research-driven enterprise, Lexaria Bioscience is based in Kelowna, British Columbia.
Lexaria’s process is also patented for delivery of THC (tetrahydrocannabinol) and psychoactive cannabinoids, including with beverages. It eliminates the necessity for sugar-filled edibles, because it facilitates flavor masking for poor tasting compounds. It also boosts bio-absorption, and THC effects are experienced within 15-20 minutes, because it can bypass first pass liver metabolism when preferred. In essence, the platform promotes healthier ingestion methods, lower overall dosing and increasing the effectiveness of lipophilic active molecules.
The company is evaluating the potential use of its DehydraTECH drug delivery platform for nicotine delivery. This platform has been shown to deliver nicotine both to the bloodstream and to the brain faster than traditional delivery systems. Nevertheless, Lexaria is not a tobacco industry partner. Moreover, its platform is an enabling technology – a complementary layer that works with the other research and development taking place on cannabinoids. If shown to be equally effective at delivering other lipophilic drugs, the platform has the potential to apply to the treatment of nervous system diseases.
Always innovating, Lexaria Bioscience continues to creatively foster growth. The company has new subsidiaries and valuable intellectual property. Recently, Chris Bunka, Lexaria Bioscience Chief Executive Officer, spoke on Uptick Newswire’s Stock Day Podcast regarding company initiatives (http://nnw.fm/p3GWY). Bunka noted that this year has been Lexaria’s busiest since its inception in 2014. The company has five licensees in the U.S. and Canada for its DehydraTECH drug delivery technology, up from only one a year ago.
Lexaria shareholders have the potential to benefit further from the company’s growing IP. The company has more than 50 patents pending in over 40 countries. It has 10 patents granted in the U.S. and Australia for the use of its DehydraTECH delivery platform. In a news release, Bunka talked about patent protection: “Our revenues are increasing. It is growing. People need to realize that our revenue creation is really closely in tune with our IP portfolio development. So, it’s hard to convince a company that should pay for our intellectual property if we don’t have it patent protected.”
Another positive growth factor for Lexaria is the establishment of four new focused subsidiaries in 2018. The emphasis of each subsidiary is hemp, nicotine, cannabis and pharmaceuticals, respectively. The four subsidiaries (Lexaria CanPharm Corp., Lexaria Nicotine Corp., Lexaria Hemp Corp. and Lexaria Pharmaceutical Corp.) are each conferred with Lexaria’s DehydraTECH drug delivery platform. Each can offer, through exclusive licensing arrangements via the parent company, the wide-ranging IP suite to their respective customers.
Lexaria Bioscience is growing by way of its licensees and gaining access to more locations and customers than ever before. With an IP family that is one of the strongest and largest in the industry, Lexaria has much to offer customers and shareholders moving forward. Its dedication to innovation is driving the company into exciting new territory.
For more information, visit the company’s website at www.LexariaBioscience.com
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
- Lexaria has its patented DehydraTECH drug delivery platform
- The company’s technology is a complementary layer that works with the other research being done on cannabinoids
- Lexaria has a robust IP portfolio and four new subsidiary companies
A drug delivery platform pioneer, Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) has developed and out-licenses its DehydraTECH technology. The company’s technology changes the way in which edible cannabinoids absorb into the body. The DehydraTECH drug delivery platform is patented for cannabidiol and all other non-psychoactive cannabinoids and enables the transportation of bioactive substances via oral ingestion. A research-driven enterprise, Lexaria Bioscience is based in Kelowna, British Columbia.
Lexaria’s process is also patented for delivery of THC (tetrahydrocannabinol) and psychoactive cannabinoids, including with beverages. It eliminates the necessity for sugar-filled edibles, because it facilitates flavor masking for poor tasting compounds. It also boosts bio-absorption, and THC effects are experienced within 15-20 minutes, because it can bypass first pass liver metabolism when preferred. In essence, the platform promotes healthier ingestion methods, lower overall dosing and increasing the effectiveness of lipophilic active molecules.
The company is evaluating the potential use of its DehydraTECH drug delivery platform for nicotine delivery. This platform has been shown to deliver nicotine both to the bloodstream and to the brain faster than traditional delivery systems. Nevertheless, Lexaria is not a tobacco industry partner. Moreover, its platform is an enabling technology – a complementary layer that works with the other research and development taking place on cannabinoids. If shown to be equally effective at delivering other lipophilic drugs, the platform has the potential to apply to the treatment of nervous system diseases.
Always innovating, Lexaria Bioscience continues to creatively foster growth. The company has new subsidiaries and valuable intellectual property. Recently, Chris Bunka, Lexaria Bioscience Chief Executive Officer, spoke on Uptick Newswire’s Stock Day Podcast regarding company initiatives (http://nnw.fm/p3GWY). Bunka noted that this year has been Lexaria’s busiest since its inception in 2014. The company has five licensees in the U.S. and Canada for its DehydraTECH drug delivery technology, up from only one a year ago.
Lexaria shareholders have the potential to benefit further from the company’s growing IP. The company has more than 50 patents pending in over 40 countries. It has 10 patents granted in the U.S. and Australia for the use of its DehydraTECH delivery platform. In a news release, Bunka talked about patent protection: “Our revenues are increasing. It is growing. People need to realize that our revenue creation is really closely in tune with our IP portfolio development. So, it’s hard to convince a company that should pay for our intellectual property if we don’t have it patent protected.”
Another positive growth factor for Lexaria is the establishment of four new focused subsidiaries in 2018. The emphasis of each subsidiary is hemp, nicotine, cannabis and pharmaceuticals, respectively. The four subsidiaries (Lexaria CanPharm Corp., Lexaria Nicotine Corp., Lexaria Hemp Corp. and Lexaria Pharmaceutical Corp.) are each conferred with Lexaria’s DehydraTECH drug delivery platform. Each can offer, through exclusive licensing arrangements via the parent company, the wide-ranging IP suite to their respective customers.
Lexaria Bioscience is growing by way of its licensees and gaining access to more locations and customers than ever before. With an IP family that is one of the strongest and largest in the industry, Lexaria has much to offer customers and shareholders moving forward. Its dedication to innovation is driving the company into exciting new territory.
For more information, visit the company’s website at www.LexariaBioscience.com
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
